Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms

Haematologica. 2014 May;99(5):797-801. doi: 10.3324/haematol.2013.097832.

Authors

Tariq I Mughal¹, Alessandro M Vannucchi, Simona Soverini, Alexandra Bazeos, Raoul Tibes, Giuseppe Saglio, Omar Abdel-Wahab, Animesh Pardanani, Rudiger Hehlmann, Tiziano Barbui, Richard Van Etten, Ayalew Tefferi, John M Goldman

Affiliation

¹ tmughal911@hotmail.com / tmughal@tuftsmedicalcenter.org.

No abstract available

Publication types

Editorial
Review

MeSH terms

Epigenesis, Genetic
Fusion Proteins, bcr-abl / genetics*
Gene Expression Regulation, Neoplastic
Humans
Janus Kinases / antagonists & inhibitors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Molecular Targeted Therapy
Myeloproliferative Disorders / diagnosis
Myeloproliferative Disorders / drug therapy
Myeloproliferative Disorders / genetics*
Neoplastic Stem Cells / drug effects
Neoplastic Stem Cells / metabolism
Prognosis
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Time Factors
Treatment Outcome

Substances

Protein Kinase Inhibitors
Fusion Proteins, bcr-abl
Janus Kinases